First OTC Low-Dose Brimonidine Eye Drop Approved for Ocular Redness

Brimonidine is a selective alpha-2 adrenergic receptor agonist
Brimonidine is a selective alpha-2 adrenergic receptor agonist

The Food and Drug Administration (FDA) has approved Lumify 0.025%, the first over-the-counter low-dose brimonidine tartrate ophthalmic solution for the treatment of ocular redness. 

Brimonidine, a selective alpha-2 adrenergic receptor agonist, works by selectively constricting the veins in the eye, increasing the availability of oxygen to surrounding tissue and reducing the likelihood of rebound redness, often associated with non-selective redness reducers. In clinical studies, low-dose brimonidine showed 95% symptom improvement at 1 minute, and reduced redness for up to 8 hours. 

Related Articles

Brimonidine is already approved in higher doses as a prescription eye drop for the treatment of intraocular pressure reduction in glaucoma patients.

Lumify is expected to be available from Bausch + Lomb in the second quarter of 2018.

For more information visit Bausch.com.